Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide

Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients. Recent insight into the heterogeneous nature of GBM suggests a more personalized approach to treatment may be necessa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Weyhenmeyer, Birgit C., Noonan, Janis, Würstle, Maximilian L., Lincoln, Frank A., Johnston, Grainne, Rehm, Markus, Murphy, Brona M.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5308652/
https://ncbi.nlm.nih.gov/pubmed/27494880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10973
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki